WO2016171640A1 - Биологически активное вещество полифармакологического действия растительного происхождения - Google Patents
Биологически активное вещество полифармакологического действия растительного происхождения Download PDFInfo
- Publication number
- WO2016171640A1 WO2016171640A1 PCT/UA2015/000101 UA2015000101W WO2016171640A1 WO 2016171640 A1 WO2016171640 A1 WO 2016171640A1 UA 2015000101 W UA2015000101 W UA 2015000101W WO 2016171640 A1 WO2016171640 A1 WO 2016171640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavonoid
- biologically active
- tricin
- glycosides
- luteolin
- Prior art date
Links
- 229940088623 biologically active substance Drugs 0.000 title claims abstract description 28
- 230000000694 effects Effects 0.000 title abstract description 26
- 229930003935 flavonoid Natural products 0.000 claims abstract description 58
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 58
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims abstract description 50
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 50
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 claims abstract description 46
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 claims abstract description 46
- -1 tricin flavonoid Chemical class 0.000 claims abstract description 46
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 41
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 39
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 34
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000009498 luteolin Nutrition 0.000 claims abstract description 28
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000008714 apigenin Nutrition 0.000 claims abstract description 27
- 229940117893 apigenin Drugs 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 26
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 22
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 22
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000005875 quercetin Nutrition 0.000 claims abstract description 22
- 229960001285 quercetin Drugs 0.000 claims abstract description 22
- 229930182486 flavonoid glycoside Natural products 0.000 claims abstract description 21
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims abstract description 19
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000007955 flavonoid glycosides Chemical class 0.000 claims abstract description 16
- 241000196324 Embryophyta Species 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 241000743799 Calamagrostis Species 0.000 claims abstract description 6
- 241000209504 Poaceae Species 0.000 claims abstract description 3
- 235000013339 cereals Nutrition 0.000 claims abstract description 3
- 230000009471 action Effects 0.000 claims description 19
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims description 10
- 229930195733 hydrocarbon Natural products 0.000 claims description 7
- 229930002875 chlorophyll Natural products 0.000 claims description 4
- 235000019804 chlorophyll Nutrition 0.000 claims description 4
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 claims description 3
- 241001148728 Calamagrostis epigeios Species 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000005069 ears Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 28
- 230000000840 anti-viral effect Effects 0.000 abstract description 21
- 241000712461 unidentified influenza virus Species 0.000 abstract description 20
- 150000003254 radicals Chemical class 0.000 abstract description 17
- 102000014150 Interferons Human genes 0.000 abstract description 12
- 108010050904 Interferons Proteins 0.000 abstract description 12
- 229940079322 interferon Drugs 0.000 abstract description 12
- 241000711549 Hepacivirus C Species 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 239000000411 inducer Substances 0.000 abstract description 8
- 208000005176 Hepatitis C Diseases 0.000 abstract description 5
- 206010022000 influenza Diseases 0.000 abstract description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract description 3
- 230000003612 virological effect Effects 0.000 abstract description 3
- 241000744363 Deschampsia Species 0.000 abstract description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract description 2
- 241000700584 Simplexvirus Species 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 208000002672 hepatitis B Diseases 0.000 abstract description 2
- 230000007813 immunodeficiency Effects 0.000 abstract description 2
- MYMGKIQXYXSRIJ-UHFFFAOYSA-N rhamnacene Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 MYMGKIQXYXSRIJ-UHFFFAOYSA-N 0.000 abstract 6
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 120
- 210000004027 cell Anatomy 0.000 description 59
- 239000013543 active substance Substances 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 36
- 229930182476 C-glycoside Natural products 0.000 description 34
- 150000000700 C-glycosides Chemical class 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000002994 raw material Substances 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 229930182470 glycoside Natural products 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000011534 incubation Methods 0.000 description 13
- 150000002338 glycosides Chemical class 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 150000002430 hydrocarbons Chemical class 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 235000008216 herbs Nutrition 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 9
- 229930182473 O-glycoside Natural products 0.000 description 9
- 150000008444 O-glycosides Chemical class 0.000 description 9
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 8
- 238000000862 absorption spectrum Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 7
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 7
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 7
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 5
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000006882 induction of apoptosis Effects 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 5
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 238000004435 EPR spectroscopy Methods 0.000 description 4
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 4
- 239000007997 Tricine buffer Substances 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- FMHKPLXYWVCLME-UHFFFAOYSA-N 4-hydroxy-valeric acid Chemical compound CC(O)CCC(O)=O FMHKPLXYWVCLME-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000286 interferogenic effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- XQISPVJWRLHHLT-UHFFFAOYSA-N 1-hydroxycyclohexa-2,4-diene-1-carboxylic acid Chemical compound OC(=O)C1(O)CC=CC=C1 XQISPVJWRLHHLT-UHFFFAOYSA-N 0.000 description 1
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 241000543810 Sasa veitchii Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ALRFYJWUVHBXLV-UHFFFAOYSA-N guaijaverin Natural products OC1COC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O ALRFYJWUVHBXLV-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003243 quercetin Chemical class 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to medicine, namely to pharmacology, and for the composition of a biologically active substance (BAS) of polypharmacological action from plant materials containing aglycone compounds of flavonoids, flavonoid glycosides and excipients.
- BAS biologically active substance
- BAS can be used to obtain drugs for the treatment and prevention of viral diseases caused by herpes viruses, influenza, hepatitis B and C, as well as virus-induced immunodeficiencies.
- a well-known molecule that has an antiviral effect in a wide spectrum is a flavonoid compound such as tricin (5,7,4 - trihydroxy-3 ', 5'-dimethoxy flavone).
- the concentration of tricin derived from Sasa albo-marginata which inhibits the development of cytomegalovirus infection at the cellular level by 50% (antiviral effect), has been found to be more than 0.42 ⁇ M (or 0.139 ⁇ g / ml) (Antiviral Research 91 (2011), 296 - 303), and the antiviral effect of synthetic tricin on group A influenza virus (H1N1) occurs at concentrations equal to and greater than 3.3 ⁇ M (or 1.09 ⁇ g / ml) (Antiviral chemistry and chemotherapy 2011, 22: 1-11; Joi 103851 / MP 1782).
- Chemically pure tricin aglycones or tricin complex compounds in combination with apigenin and / or luteolin and / or quercetin compounds are obtained from plant materials: bamboo leaves, Sasa, rice leaves. Chemically pure flavonoid compounds are rapidly oxidized and hydrophobic, therefore their use is limited to the field of scientific research at the cellular level. (Microbes and Infection. 2012 p. V.14. Is. 12. p 1086-1092).
- glycides of aglycones of tricin, apigenin, luteolin, quercetin and their complexes are hydrophilic and complexes of different molecular flavonoid compounds at the level of the whole organism have a synergistic effect and increased bioavailability compared to the action of individual pure substances. (In vivo 201 1, 25 (5), 757-762, Journal of Food. Vol. 13, Xs 1, p. 140-150).
- the closest chemical composition and origin to the present invention is a biologically active substance (BAS) from plant materials for the treatment and prevention of pathological conditions, obtained by the method described in patent UA N ° 54362 7MPK A61K 35/78 from 02.17.2003 Bull. jNo 2.
- BAS biologically active substance
- As a plant raw material a mixture of plants of the genus Calamagrostis Adans and the genus Deschampsia Beauv is used, which are collected in the period after the stems are thrown out and until the flowering of the spikelets.
- Such a biologically active substance is characterized by a fairly low toxicity, provides a wide range of pharmacological effects on the human body, but there is no definition of the specific composition of active substances and no activity is determined against specific viruses, there are no recommended dosages for creating dosage forms.
- the task was to improve BAS with the determination of specific compositions of the active components of BAS, their physico-chemical, biological properties, determine its optimal composition for antiviral effect on specific viruses, dosages when creating dosage forms while maintaining low toxicity of BAS.
- the biologically active substance of polypharmacological action obtained from the green parts and spikelets of cereal plants of the Gramineae family, the genus Calamagrostis Adans and / or the genus Deshampsia Beauv, contains flavonoids, in particular, aglycones of flavonoids tricin (tricin), apigenin, luteolin, quercetin, ramnazine and / or flavonoid glycosides of tricin, apigenin, luteolin, quercetin, ramnazine, excipients and has the following composition, wt%: aglycone of flavonoid tricin and / or its flavonoid glycosides from 0.016 to 2.062% ; apigenin flavonoid aglycone and / or flavonoid glycosides thereof from 0.010 to 1.393%; aglycone of the luteolin fla
- the biologically active substance as auxiliary substances contains hydrocarbon compounds, amino acids, chlorophylls.
- the biologically active substance is obtained from terrestrial Veinik (Calamagrostis epigeios L., genus Calamagrostis Adans) and / or Shchuchka sod (Deshampsia caespitosa L., genus Deshampsia Beanu).
- the content of O-glycosidic forms of flavonoids in the biologically active substance is (53.545 + 86.422)%, and C-glycosidic forms of flavonoids is (43.293 4.910)% of the total number of flavonoid compounds, the rest are flavonoid aglycones.
- model extracts Five series of model extracts from herbs of different harvesting seasons were made. A series of model extracts consisted of total extracts: a mixture of terrestrial Veinik and Shchuchka herbs taken in a ratio of 1: 1, and from each herb separately with a weight ratio of raw materials: ethyl alcohol in the range from 1: 10 to 3: 1. Five series of extracts are involved in order to obtain the boundaries of the range of fluctuations in the content of the investigated substances and determine their average values. Model extracts were obtained by known extraction methods, namely: maceration, percolation, ultrasonic extraction and a combination of these methods, (Innovative technologies and equipment for pharmaceutical production (edited by N.V. Menshutina) v.2 (p.
- composition of biologically active substances was determined using instrumental analytical physical chemistry methods, namely: high-performance high-speed liquid chromatography with diode-matrix detection (HPLC, UPLC-PDA); gas chromatographic mass spectrometry with electron impact ionization (GC-MS); high performance liquid chromatography with a mass detector during ionization by electronic spray (UPLC-MC / MS); nuclear magnetic resonance (NMR).
- HPLC high-performance high-speed liquid chromatography with diode-matrix detection
- GC-MS gas chromatographic mass spectrometry with electron impact ionization
- UPLC-MC / MS high performance liquid chromatography with a mass detector during ionization by electronic spray
- NMR nuclear magnetic resonance
- Biologically active substances are contained in plants in trace amounts against the background of macrocomponents: chlorophylls, plant fiber, therefore, the first step in isolating biologically active substances is the removal of macrocomponents.
- a chlorophilic (fat-soluble) fraction that is hydrophobic is removed with an organic solvent, for example hexane or chloroform.
- Hydrocarbons in plant materials are represented by mono- and polysaccharides both in a free state and in combination with aglycones that have a hydroxyl group. Free hydrocarbons, which are characterized by hydrophilic properties, are removed by extraction, that is, the aglycones are extracted, and the hydrocarbons remain in the aqueous phase. Since flavonoid aglycons in plants are present both in a free state and in the form of glycosidic forms, therefore, after removal of the chlorophyll fraction, for qualitative and quantitative determination it is necessary to convert all aglycones (free and glycosidic) into one analytical form - aglycones without hydrocarbon fragments. This problem is solved by acid hydrolysis: as a result of the action of hydrogen ions on the glycosidic forms of flavonoids, the removal of hydrocarbon fragments occurs.
- flavonol and flavono glycoside compounds are established by studying the hydrolysis products by spectrophotometric, chromatographic (HPLC, GC with various detectors) methods.
- Fig.Z HPLC, UPLC-PDA chromatogram of preparatively isolated compounds of the dominant tricin aglycon and its absorption spectra.
- Figure 4. GC-MS chromatogram of TMS derivatives of the compounds of the dominant tricin aglycone (ion composition spectrum).
- Fig. 8 Dominant aglycones of biologically active substances and their names.
- Figure 10 A calibration graph of the peak area of the mass of 271 as a function of concentration.
- FIG. 13 A calibration graph of the dependence of the peak area of the mass of 465 on the concentration.
- FIG. 14 The effect of the concentration of hydrogen ions (the number of moles of HC1) on the stability of hyperoside and vitexin when heating solutions for 120 minutes in a boiling water bath.
- FIG. 16. 2 - total mass chromatogram when scanning by the masses of individual ions; FIG. 16. .UPLC-MC / MS. Where: 3 - scanning by weight 331, determination of the areas of chromatographic peaks;
- FIG. 4 is a chromatogram of a scan by mass 331.
- FIG. 17. UPLC-MC / MS.
- FIG. 19 HPLC, UPLC-PDA chromatograph and absorption spectra of the chromatographic peaks of the ethanol extract of Weinik terrestrial.
- Fig.20 HPLC, UPLC-PDA chromatograph and absorption spectra of the chromatographic peaks of the ethanol extract of Soddy Schuchka.
- Fig.21 The effect of biologically active substances on the growth of Jurkat cells.
- Fig.22 The percentage of hypodiploid cells in Jurkat culture after incubation with biologically active substances.
- Fig.23 The content of hypodiploid cells in the Jurkat culture after incubation with biologically active substances for 2 days and subsequent induction of apoptosis with vepezid.
- Fig. The effect of biologically active substances on the rate of generation of superoxide radical by Namalwa cells.
- Fig. 26 The effect of biologically active substances on the rate of generation of superoxide radical by the homogenate of MT-4 cells.
- Fig. 27 The effect of biologically active substances on the chemoluminescence of MT-4 cells induced by hydrogen peroxide. Due to the large amount of graphic material, for a better understanding of the meaning, the names of the figures are also affixed next to them.
- FIG. 1 A typical chromatogram of the total compounds (weight ratio of raw materials: ethyl alcohol is 1: 2) of an extract diluted with ethanol 96% in a 1: 1 ratio obtained by HPLC with a diode-matrix detector is shown in FIG. 1.
- the analysis was performed using a UPLC Waters chromatograph ACCENCY VENSE column 18, 1.7 ⁇ m, 2, 1 x 150 mm under the following conditions: sample volume 1 ⁇ l, thermostat temperature 30 ° C, mobile phase velocity 0.3 ⁇ l / min ., detection at 350 nm.
- Figure 1 also provides absorption spectra of chromatographically isolated compounds of the total extract (Spectrum Index Fraction Plot).
- Acid hydrolysis was carried out as follows: hydrochloric acid was added to the extract to obtain a solution with a pH of about 2 (2 M hydrochloric acid each), the flask with the solution, connected to a reflux condenser, was kept for 2 hours in a boiling water bath , cooled, hydrolyzed aglycones and glycosidic forms are isolated with ethyl acetate, the organic solvent is removed in vacuo, and the residue is dissolved in ethanol (9: 1) and analyzed.
- the compound from group 2 which is dominant and has a typical flavone spectrum, was isolated using preparative HPLC Waters XBridgeTM prep CI 8 ⁇ OBD TM 19 x 250 mm reverse phase chromatography (Mobile phase: methanol - water (1: 9), flow rate 15 ml / min.) With repeated introduction and purification of chromatographic fractions. As a result, 1 1 mg of aglycon was isolated (HPLC chromatogram in Fig. 3). To determine the gross formula and structure of an aglycon molecule, the GC method with a mass spectrometric detector was used.
- the detected structure of the dominant aglycone was confirmed by NMR using the tricin standard (Hangzhou Dayangchem Co., LTD. CAS Na: 520-32-1 Purity: 98.5%), as well as comparing the isolated tricin with tricin isolated from leaves bamboo according to the methodology of Chinese researchers (J. Agric. Chem. 2007,55,10086-10092). According to the above methodology, the presence and identification (except for tricin) of the following flavonoid aglycones was determined and identified (except for tricin): flavones — apigenin, luteolin; flavonols - quercetin, ramnazine (Fig. 8).
- Flavonoid aglycones according to well-known literature data, for example (US Patent N ° US 2008/0171708 dated 06/17/2006), and our studies, in plant materials and extracts obtained from it, are most often found in the form of O and / or C-glycosides, (Fig. 9), as well as individual aglycones, can be in the form of O- and C-glycosides simultaneously.
- the hydrocarbons present in the extract are first determined and identified using a GC with a mass detector (using TMS derivatization and also using HPLC with a mass spectrophotometric detector for electrospray ionization (this method allows to determine the most intense fragment that corresponds to the molecular ion (m / z).
- the hydrocarbon compounds in the model extracts that have been identified are given in Table 1.
- the quantification of aglycones and / or glycosides by the masses of individual ions is carried out using calibration graphs according to the standards: tricin, apigenin, luteolin, quercetin, ramnazine, vitexin, hyperoside.
- FIG. 10, 11, 12, 13 are examples of calibration plots of agricones of tricin, apigenin, and also hyperoside (O-glycoside) and 1,6-anhydro-p-D-glycoside of vitexin (C-glycoside).
- O- and C-glycosides The most optimal conditions for the quantitative determination of O- and C-glycosides is a concentration of hydrogen ions of 0.08 mol by hydrochloric acid (HC1). Under such conditions, O-glycosides are completely destroyed, and C-glycosides remain (by 83%). (The dynamics of the destruction of O- and C-glycosides on the example of vitexin and hyperoside is shown in Fig. 14). So, to obtain information on the quantitative content of aglycones, O- and C-glycosidic forms of aglycones, the results of studies of the extract and product after hydrolysis in an environment of 0.08 mol of HC1 by HPLC, UPLC-MC / MS are analyzed. In FIG.
- FIG. 15 shows an example of a PDA chromatogram (1) and the total mass chromatograms (2) when scanning for individual ions (the retention time on a UPLC MS / MS device is slightly shorter than the retention time on a Waters UPLS - PDA device with the same column) of the total extract before hydrolysis. Also in FIG. 16. An example of scanning by weight 331 (tricin) with the determination of areas of chromatographic peaks (3) and PDA chromatograms of scanning by weight 331 (4) is given. In FIG. 17 and FIG. Figure 18 shows an example of scanning the total extract and an example of scanning by weight 331 of the total extract after hydrolysis.
- the results of analysis of the total extract and the results obtained after hydrolysis were compared: the absence or decrease of the peak after hydrolysis indicates the presence of O-glycoside, which can be present both independently (a separate chromatographic peak) and in the complex of compounds (decrease chromatographic peak, which contains several compounds after hydrolysis).
- the theoretical value of the mass of ions of glycosidic compounds was used taking into account the masses of extracted aglycones, which are shown in Table 3, and identified carbohydrates (Table 1).
- Vercetin 8-C-glycoside 465 8-C-aporinin glucuronide 447 quercetin 435
- O - glycosides (mg / l) in terms of hyperoside in the total extract from a mixture of herbs (1: 1) with a weight ratio of raw materials: ethyl alcohol in the range from 1:10 to 3: 1
- the compounds of group 1 (Fig. 1) on the HPLC chromatogram, with the lowest retention time, as the most hydrophilic, are a mixture of O- and C-glycosides isolated above aglycones, of which tricin, luteolin, apigenin are dominant.
- the compounds of group 2 (Fig. 1) are a mixture of free aglycones.
- Group 3 compounds are acylated forms of O-, C-, and bi-glycosides.
- Comparative composition and boundaries of deviations of the content (mg / l) of free aglycones, O- and C-glycosides in model extracts from a mixture of herbs (1: 1) and from each herb separately with a weight ratio of raw materials: ethyl alcohol in the range from 1:10 to 3: 1.
- the weight ratio of raw materials ethyl alcohol (dry residue%; density
- the largest percentage (concentration) of a mixture of flavonoid compounds contains an extract from a mixture of herbs (1: 1) with a weight ratio of raw materials: extractant equal to 3: 1, equal to 9.408% (3223, 9 mg / l) of the dry residue: 30300 mg / l.
- the smallest amount of flavonoid compounds (0.132% or 9.870 mg / l with a dry residue equal to 6240 mg / l) contains terrestrial Weinik extract with a ratio of raw material: extractant equal to 1: 10.
- herpes type 2 virus used herpes type 2 virus, strain BH (HSV), infectious titer: 5.0-g 7.0 lg TCD50 / OD ml (TCD50 - tissue cytopathogenic dose of the virus, causes damage to 50% of the cell monolayer).
- HSV herpes type 2 virus
- infectious titer 5.0-g 7.0 lg TCD50 / OD ml
- TCD50 tissue cytopathogenic dose of the virus, causes damage to 50% of the cell monolayer.
- the cultures were incubated in a thermostat with a supply of COg for 5 days, daily monitoring with a microscope and noting the reproduction of the virus by the cytopathic effect of HSV on Vero cells compared to control cultures where the monolayer was not treated with extracts (virus control).
- the cytopathic effect of HSV on cells morphologically manifests itself in the formation of symplasts or rounded cells in combination with proliferation and giant multinucleated cells.
- Table 9 shows the indicators of maximum tolerated concentration (MIC), minimum active concentration (MAA) and chemotherapeutic index (CTI).
- the studied extracts effectively suppress type 2 herpes virus.
- the minimum active concentration at which the development of a virus-specific action is suppressed by 2.0 - 3.0 lg TCD50 for the Shchuchka extract of soddy was 0.017 ⁇ g / ml, which is half the value of the minimum active concentration (0.034 ⁇ g / ml) for the total extract and extract of Weinik terrestrial.
- the HTI of all extracts was approximately 160.
- Example 2 Determination of the anti-influenza activity of extracts in in vitro experiments.
- Influenza virus was used, strain A / FM / 1/47 (H1N1), the infectious titer of the allantoic culture was 6.0 lg EID50 / 0.2 ml.
- a continuous, continuous layer MDC cell culture (dog kidney cells) was used. Cells were grown in plates on RPMI-1640 medium + 10% fetal serum (Nunclon, Surface, Denmark) at a temperature of 37 ° C in a thermostat with a supply of C0 2 . To increase the sensitivity of cells to infection with their influenza virus, trypsin treatment was performed. Trypsin stock solution was prepared by adding up to 3 g of an enzyme sample in 3 ml of DMEM growth medium. Cells were washed three times with this solution at 50 ml per well.
- the growth medium was poured, model extracts were added to the cells in different concentrations, and the influenza virus was introduced at a dose of 100 TCTs50.
- Cultures were incubated in an incubator with C0 2 feed for 3 days, daily monitoring using a microscope.
- the chemotherapeutic index (CTI) of model extracts in relation to the influenza virus was determined by establishing the ratio of the maximum tolerated concentration (MIC) to the minimum active concentration (MAC), at which the development of the virus-specific cytopathic effect is suppressed by 2.0 - 3.0 lg IDso ( Table 11).
- Bovine viral diarrhea virus which is a test model of hepatitis C virus, was used as a surrogate virus for HCV.
- Antiviral activity was studied in a culture of MDVC, which was treated with different dilutions of the extracts and VBVD was added at a dose of 100 TCD50. The cultures were incubated in a thermostat until a specific cytopathic effect virus in the control, and then in the culture medium was determined infectious titer of the virus. The results are presented in table 12.
- model extracts are effective inhibitors of hepatitis C surrogate virus (VBVD) with a high CTI.
- Interferonogenic activity was studied in an in vivo experiment on outbred white mice to which model extracts were injected intraperitoneally (0.1 ml each) at a concentration of 55.5 ⁇ g / kg. After 24 hours, the mice were withdrawn from the experiment by euthanasia and interferon (IFN) was determined in blood serum according to the generally accepted method for suppressing the cytopathogenic effect (CPD) of vesicular stomatitis virus (VVS) in homologous tissue culture L929. The type of IFNa was determined by the acid sensitivity marker. For this purpose, blood serum was divided into two equal parts. In one of them, the pH of the liquid with 4 N HC1 was adjusted to 2.0, left at 4 ° C for 24 hours, and then the pH of the liquid was restored with 4 N NaOH to 7.2.
- IFN interferon
- Poly I Poly C - reference inducer IFN (Calbiocheus, USA)
- flavonoid substances are quite actively studied in terms of the induction of apoptosis and the effect on cell differentiation, since they have a selective effect on leukemia and normal cells.
- cytotoxicity For analysis of cytotoxicity, induction of apoptosis, and phase distribution of the cycle, biologically active substances were introduced into the culture medium of suspension cultures at the concentration indicated below. Cell viability was determined by trypan blue staining. At the end of the incubation with the appropriate substances, the cytocentrifuged cell preparations were stained according to Pappenheim.
- apoptotic index was calculated by the formula: (number of apoptotic cells / total number of cells) x 100).
- Phase distribution of the cell cycle was studied in cells stained with propidium iodide using flow cytometry.
- test substance is low toxic. These data coincide with the relative non-toxicity of the extracts on other, both suspension and monolayer cell cultures, used to study the antiviral effect.
- the data obtained indicate that the biologically active substance causes a pro-apoptotic effect, and with an increase in concentration - an apoptotic effect.
- vepezid To determine the possible modifying effect of flavonoid substances on the induction of apoptosis of Jurkat cells by vepezid, the cells were first incubated with biologically active substances, and then after 2 or 3 days, vepezid was added to the cells at a dose of 1 ⁇ mol / L for 1 day, i.e., vepezid was used under conditions of sufficient but not excessive, for the induction of apoptosis. The results are shown in Fig.23.
- the superoxide radical generation rate was determined on an EPR spectrometer using a spin trap of 2,2,6,6-tetramethylpiperidine-K-oxide (TEMPO), which forms a stable TEMPO radical with a short-lived superoxide.
- TEMPO 2,2,6,6-tetramethylpiperidine-K-oxide
- the reaction of the accumulation of stable TEMPO radicals in the cuvette of the EPR spectrometer after introducing trap cells into the suspension proceeded linearly for 5-6 minutes. Spectra were recorded at minute intervals.
- the accumulation rate of the TEMPO radical which corresponds to the rate of generation of the superoxide anion radical, was recorded.
- the working volume of the cuvette was 170 ⁇ l. Studies were carried out at room temperature. Native (whole) cells were introduced into the cuvette or homogenized in an ice bath immediately before the spectrometer was added to the cuvette. Additionally examined cells, either preheated (5 min., 60 ° C), or after exposure at 0-10 C in order to inactivate or inhibit the enzymes that are involved in the electron transfer chain. All solutions were prepared ex tempore from recrystallized reagents of the brand “analytical grade (pure for analysis)” and distilled water.
- the rate of generation of the superoxide radical anion decreased by 20-30% after 2 hours of incubation, and more than half after 4 hours of incubation. After 24 hours of incubation, the rate of generation of this radical was close to zero.
- Tests of biologically active substances indicate the presence of antioxidant properties, namely, the dose-dependent kinetics of suppressing the generation of superoxide radical anion, as well as the inhibition of the intensity of free radical processes induced by hydrogen peroxide, are confirmed.
- the intensity of free radical processes was studied by the chemiluminescent method at room temperature. Hydrogen peroxide was used as an inductor of the generation of radical forms of oxygen, which was introduced into the chemiluminometer cell at the rate of 0.5 ml of 3% H 2 O 2 per 1 ml of cell suspension after preliminary registration of the basic level of cell luminescence with an open PMT curtain (photoelectron multiplier). Cells washed from the culture medium were injected at a concentration of 1 to 8 million / ml. Incubation of MT-4 cells with biologically active substances significantly changed the chemiluminescence intensity of cells attacked by H2O2. Typical chemiluminograms are shown in FIG. 27.
- biologically active substances are substances of polypharmacological action.
- the biological spectrum of the action of biologically active substances obtained from a mixture of terrestrial Veinik and Shchuchka soddy herbs (1: 1), and the spectrum of biological activity of biologically active substances obtained from each herb separately, is the same and depends only on the concentration of substances in terms of the total amount of flavonoid compounds.
- the improvement of biologically active substances with the determination of specific compositions of active substances of biologically active substances, their physico-chemical, biological properties leads to the invention of its optimal composition for antiviral action for specific viruses, dosages when creating dosage forms.
- BAS is an inducer of endogenous interferon type (y), has an apoptomodulating effect, has antioxidant properties and increases cell resistance to free radical stress.
- the antiviral effect for specific viruses was defined as the antiviral effect against herpes simplex virus type 2, influenza virus, bovine diarrhea virus (hepatitis C virus).
- the compounds that make up the biologically active substances have the ability to block the development of both DNA and RNA-containing viruses.
- the studied extracts effectively suppress type 2 herpes virus.
- the minimum active concentration at which the development of virus-specific action is suppressed 2.0 - 3.0 lg TCD50, for the Shchuchka soddy extract was 0.017 ⁇ g / ml, which is two times less than the minimum active concentration (0.034 ⁇ g / ml) for the total extract and terrestrial Veinik extract.
- the HTI of all extracts was approximately 160.
- model extracts are effective against influenza virus.
- the infectious titer of the influenza virus decreases the most (by 3.0 lg ID50) at a concentration of biologically active substances equal to 0.0034 ⁇ g / ml under the action of the extract of Shchuchka sod.
- the results of studies show that model extracts are effective inhibitors of hepatitis C surrogate virus (VBVD) with high HTI.
- the concentration of biologically active substances to obtain the antiviral effect of 0.017 g 0.068 ⁇ g / ml is significantly less than that for synthetic substances.
- Terrestrial veinica induces interferon at the level of the reference inducer Poly I: Poly C, and the total extract and extract of Soddy tussock induce interferon at a level of 25% of the level of interferon induction by the reference inducer.
- Tests of biologically active substances indicate the presence of antioxidant properties, namely, the dose-dependent kinetics of suppressing the generation of superoxide radical anion is confirmed, as well as the inhibition of the intensity of free radical processes induced by hydrogen peroxide.
- the proposed BAS does not have the drawbacks inherent in synthetic antiviral drugs, provides the ability to create dosage forms with an accurate dosage and targeted pharmaco dynamic action.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/569,076 US20180133278A1 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
EP15890050.6A EP3195872A4 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
MX2017013696A MX2017013696A (es) | 2015-04-24 | 2015-10-28 | Sustancia biologicamente activa proveniente de una planta que tiene un efecto polifarmacologico. |
BR112017021292-7A BR112017021292A2 (pt) | 2015-04-24 | 2015-10-28 | substância biologicamente ativa à base de plantas com efeito polifarmacológico |
AU2015391981A AU2015391981B2 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
CA2983299A CA2983299C (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
EA201700340A EA033232B1 (ru) | 2015-04-24 | 2015-10-28 | Биологически активное вещество полифармакологического действия растительного происхождения |
KR1020177032242A KR102461853B1 (ko) | 2015-04-24 | 2015-10-28 | 식물 기원의 다원 행동 생물학적 활성 물질 |
CN201580079170.6A CN107530390A (zh) | 2015-04-24 | 2015-10-28 | 多药性作用植物生物活性物质 |
US16/748,762 US20220000962A1 (en) | 2015-04-24 | 2020-01-21 | Plant-based biologically active substance having a polypharmacological effect |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201503915 | 2015-04-24 | ||
UAA201503915 | 2015-04-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/569,076 A-371-Of-International US20180133278A1 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
US16/748,762 Division US20220000962A1 (en) | 2015-04-24 | 2020-01-21 | Plant-based biologically active substance having a polypharmacological effect |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016171640A1 true WO2016171640A1 (ru) | 2016-10-27 |
WO2016171640A8 WO2016171640A8 (ru) | 2018-03-08 |
Family
ID=67998792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/UA2015/000101 WO2016171640A1 (ru) | 2015-04-24 | 2015-10-28 | Биологически активное вещество полифармакологического действия растительного происхождения |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180133278A1 (ru) |
EP (1) | EP3195872A4 (ru) |
KR (1) | KR102461853B1 (ru) |
CN (1) | CN107530390A (ru) |
AU (1) | AU2015391981B2 (ru) |
BR (1) | BR112017021292A2 (ru) |
CA (1) | CA2983299C (ru) |
EA (1) | EA033232B1 (ru) |
MX (1) | MX2017013696A (ru) |
WO (1) | WO2016171640A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796016A (zh) * | 2022-05-31 | 2022-07-29 | 浙江伊瑟奇医药科技有限公司 | 一种私密修护精华液及其制备方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
WO2018157081A1 (en) | 2017-02-27 | 2018-08-30 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
WO2018170457A1 (en) | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
WO2021262749A1 (en) * | 2020-06-26 | 2021-12-30 | Research Cancer Institute Of America | Compositions and methods for preventing and/or treating viral infection |
CN113880898B (zh) * | 2020-10-30 | 2023-07-25 | 杭州拉林智能科技有限公司 | 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058285A1 (fr) * | 2002-12-26 | 2004-07-15 | Anatoliy Matveyevich Novyk | Procede permettant d'obtenir une substance biologiquement active |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007054985A1 (de) * | 2007-11-17 | 2009-05-20 | Gerhard Dr. Sauermann | Topische Produkte zur Reduzierung der Häufigkeit von Rezidiven bei Lippenherpes |
WO2009129818A1 (en) * | 2008-04-21 | 2009-10-29 | Herbonis Ag | Preparation and use of a plant extract from solanum glaucophyllum with an enriched content of 1,25-dihydroxyvitamin d3 glycosides and quercetin glycosides |
-
2015
- 2015-10-28 MX MX2017013696A patent/MX2017013696A/es unknown
- 2015-10-28 EA EA201700340A patent/EA033232B1/ru unknown
- 2015-10-28 EP EP15890050.6A patent/EP3195872A4/en active Pending
- 2015-10-28 KR KR1020177032242A patent/KR102461853B1/ko active IP Right Grant
- 2015-10-28 CA CA2983299A patent/CA2983299C/en active Active
- 2015-10-28 WO PCT/UA2015/000101 patent/WO2016171640A1/ru active Application Filing
- 2015-10-28 AU AU2015391981A patent/AU2015391981B2/en active Active
- 2015-10-28 US US15/569,076 patent/US20180133278A1/en not_active Abandoned
- 2015-10-28 BR BR112017021292-7A patent/BR112017021292A2/pt not_active IP Right Cessation
- 2015-10-28 CN CN201580079170.6A patent/CN107530390A/zh active Pending
-
2020
- 2020-01-21 US US16/748,762 patent/US20220000962A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058285A1 (fr) * | 2002-12-26 | 2004-07-15 | Anatoliy Matveyevich Novyk | Procede permettant d'obtenir une substance biologiquement active |
Non-Patent Citations (6)
Title |
---|
BURLAKA I. C. ET AL.: "«Oderzhannia ta shchentifshashchia nastoiki travi kunichnika zvichainogo ta travi shchuchnika dernistogo»", MATERIALY I MKNARODNO1 NAUKOVO-PRAKTICHPOL 1 NTERNET-KONFERENTSL «TEKHNOLOGICHNI TA BIOFARMATSEVTICHNI ASPEKTI STVORENNIA LIKARSKIKH PREPARATIB RIZNOI NAPRAVLENOSTI DII», 2014, pages 34, XP009502615 * |
BURLAKA I. S.: "«Farmakognostichne vivchennia Calamagrostis epigeios (L.) roth. I Deshampsia caespitosa (L.) beauv.»", AVTOREFERAT, DIP. KAND. FARM., 2013, nauk, KHarkiv, pages 1 - 23, XP009502647 * |
JEFFREY B. HARBORNE ET AL.: "«Flavonoid patterns in leaves of the Gramineae»", BIOCHEMICAL SYSTEMATICS AND ECOLOGY», vol. 4, no. 4, 1976, pages 267 - 280, XP025577076 * |
KISLICHENKO V. S. ET AL.: "«Flavonoids from the aerial part of Calamagrostis epigeios»", CHEMISTRY OF NATURAL COMPOUNDS, vol. 49, no. 1, 2013, pages 133 - 134, XP018507695 * |
See also references of EP3195872A4 * |
STAROSILA D. B.: "«Flavonoidy-geterotsiklicheskie kislorodsoderzhaschie soedineniia, obladauschie shirokim spektrom antivirusnoi aktivnosti», tezisy dokladov nauchno-prakticheskoi konferentsii «Biologicheski aktivnye veshchestva: fundamentalnye i prikladnye voprosy polucheniia i primeneniia»", NOVY SVET, 23 May 2011 (2011-05-23), Krym, Ukraina, pages 607, XP009502619 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796016A (zh) * | 2022-05-31 | 2022-07-29 | 浙江伊瑟奇医药科技有限公司 | 一种私密修护精华液及其制备方法 |
CN114796016B (zh) * | 2022-05-31 | 2023-03-24 | 浙江伊瑟奇医药科技有限公司 | 一种私密修护精华液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2015391981A1 (en) | 2017-11-30 |
MX2017013696A (es) | 2019-07-29 |
KR20170139049A (ko) | 2017-12-18 |
AU2015391981B2 (en) | 2021-08-19 |
EP3195872A1 (en) | 2017-07-26 |
BR112017021292A2 (pt) | 2018-12-04 |
WO2016171640A8 (ru) | 2018-03-08 |
CN107530390A (zh) | 2018-01-02 |
KR102461853B1 (ko) | 2022-10-31 |
EP3195872A4 (en) | 2018-04-11 |
US20180133278A1 (en) | 2018-05-17 |
CA2983299C (en) | 2022-12-06 |
EA033232B1 (ru) | 2019-09-30 |
EA201700340A1 (ru) | 2017-10-31 |
US20220000962A1 (en) | 2022-01-06 |
CA2983299A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220000962A1 (en) | Plant-based biologically active substance having a polypharmacological effect | |
Jun et al. | Cytotoxic activity of [beta]-Caryophyllene oxide isolated from jeju guava (Psidium cattleianum sabine) leaf | |
Mohammed et al. | Flavonoid constituents, cytotoxic and antioxidant activities of Gleditsia triacanthos L. leaves | |
Nguyen et al. | New prenylated isoflavonoids as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Erythrina addisoniae | |
Yadav et al. | Antioxidant furofuran lignans from Premna integrifolia | |
Dang et al. | α-Glucosidase inhibitors from the leaves of Embelia ribes | |
Jiang et al. | Flavonoids from Curcuma longa leaves and their NMR assignments | |
Na et al. | Antioxidant compounds from the stem bark of Sorbus commixta | |
Farid et al. | Comprehensive phytochemical characterization of Raphanus raphanistrum L.: in vitro antioxidant and antihyperglycemic evaluation | |
Liu et al. | Structural features guided “fishing” strategy to identification of flavonoids from lotus plumule in a self-built data “pool” by ultra-high performance liquid chromatography coupled with hybrid quadrupole-orbitrap high resolution mass spectrometry | |
Messi et al. | Phenolic compounds from the roots of Ochna schweinfurthiana and their antioxidant and antiplasmodial activities | |
Cui et al. | Analysis of bioactive constituents from the leaves of Amorpha fruticosa L. | |
Shimoda et al. | Glycosylation of hesperetin by plant cell cultures | |
Besbas et al. | Chemical composition, antioxidant, antihemolytic and anti-inflammatory activities of Ononis mitissima L. | |
CN108129295A (zh) | 一类松香烷型二萜衍生物与其药物组合物和用途 | |
Farid et al. | Comparative study of Posidonia oceanica L.: LC/ESI/MS analysis, cytotoxic activity and chemosystematic significance | |
Noté et al. | Pro-apoptotic activity of acylated triterpenoid saponins from the stem bark of Albizia chevalieri Harms | |
Gadetskaya et al. | Phytochemical characterization and biological activity of secondary metabolites from three Limonium species | |
Sugimoto et al. | Structure elucidation of secondary metabolites isolated from the leaves of Ixora undulate and their inhibitory activity toward advanced glycation end-products formation | |
Kolodziej | Studies on Bignoniaceae: newbouldiosides D–F, minor phenylethanoid glycosides from Newbouldia laevis, and new flavonoids from Markhamia zanzibarica and Spathodea campanulata | |
Burton et al. | Elucidation of a new oleanane glycoside from Barringtonia asiatica | |
Farid et al. | Phytochemical constituents of the butanol fraction of Arum palaestinum Boiss.: cytotoxic and antiviral screening | |
KR101306875B1 (ko) | 풍년화 추출물을 유효성분으로 포함하는 종양의 예방 또는 치료용 약제학적 조성물 | |
Wang et al. | On-line identification of the chemical constituents of Polygoni Multiflori Radix by UHPLC-Q-ToF MS/MS | |
Hamdan et al. | Secondary metabolites isolated from dichloromethane fraction of rough lemon stem and hepatoprotective effect of limonianin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15890050 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015890050 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201700340 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017021292 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2983299 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15569076 Country of ref document: US Ref document number: MX/A/2017/013696 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20177032242 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015391981 Country of ref document: AU Date of ref document: 20151028 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017021292 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017021292 Country of ref document: BR Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2477, SOLICITA-SE QUE A EXIGENCIA SEJA RESPONDIDA CORRETAMENTE, NUM PRAZO DE 60 DIAS, POR MEIO DA GRU DE CODIGO 207, ESPECIFICO PARA ESSE TIPO DE SERVICO. DEVE SER FEITO O PAGAMENTO DE DUAS GRUS 207, UMA REFERENTE A PUBLICACAO RPI 2477 E OUTRA REFERENTE A ESTE ADITAMENTO. |
|
ENP | Entry into the national phase |
Ref document number: 112017021292 Country of ref document: BR Kind code of ref document: A2 Effective date: 20171004 |